Publication:
Does growth hormone treatment advance bone age?

dc.contributor.buuauthorSağlam, Halil
dc.contributor.buuauthorSAĞLAM, HALİL
dc.contributor.buuauthorTarım, Ömer
dc.contributor.buuauthorTARIM, ÖMER FARUK
dc.contributor.buuauthorSalı, Enes
dc.contributor.buuauthorEren, Erdal
dc.contributor.buuauthorEREN, ERDAL
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı.
dc.contributor.orcid0000-0002-6598-8262
dc.contributor.orcid0000-0002-1684-1053
dc.contributor.orcid0000-0002-5322-5508
dc.contributor.researcheridJPK-3909-2023
dc.contributor.researcheridC-7392-2019
dc.date.accessioned2024-09-25T06:00:35Z
dc.date.available2024-09-25T06:00:35Z
dc.date.issued2017-08-01
dc.description.abstractIntroduction: Growth hormone (GH) treatment may have a stimulatory effect on bone maturation which raises concern about acceleration of bone maturation leading to early epiphyseal fusion. In this study, we aimed to investigate this possibility and determine whether or not accelerated bone maturation affects predicted or final height.Methods: A total of 230 patients who received GH treatment between 1995 and 2005 were retrospectively studied. The patients were classified as isolated growth hormone deficiency (GHD) (Group-1), Turner syndrome (Group-2), and others (Group-3). The previous X rays were obtained from the medical records and follow-up X rays were requested during the clinic visit. Bone age (BA) assessment was done according to the atlas of Greulich and Pyle. Based on BA, adult height prediction was calculated by the method of Bayley and Pinneau. The predicted height (PH) at baseline and after the first and second years of treatment were evaluated along with the change in chronological age (CA)-BA and CA/BA.Results: Height SDS significantly increased in all three groups (p<0.05). CA-BA decreased in Groups-1 and 2 during the first and second years of treatment (p<0.05). The BA acceleration was verified by the decrement in CA/BA ratio. However, predicted height was not negatively influenced despite BA advancement.Discussion and Conclusion: BA advances with GH treatment as evident from the reduction in CABA and CA/BA. However, predicted height is not adversely affected by accelerated bone maturation in our cohort over two years of treatment. This issue needs to be investigated in other patient groups such as precocious puberty where bone maturation is further accelerated.
dc.identifier.endpage49
dc.identifier.issn1304-9054
dc.identifier.issue2
dc.identifier.startpage42
dc.identifier.urihttps://hdl.handle.net/11452/45179
dc.identifier.volume15
dc.identifier.wos000431779900006
dc.indexed.wosWOS.ESCI
dc.language.isoen
dc.publisherGalenos Yayincilik
dc.relation.journalGuncel Pediatri-journal Of Current Pediatrics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.subjectIdiopathic short stature
dc.subjectDeficient children
dc.subjectMaturation
dc.subjectPuberty
dc.subjectTherapy
dc.subjectHeight
dc.subjectBoys
dc.subjectGrowth hormone deficiency
dc.subjectGrowth hormone treatment
dc.subjectTurner syndrome
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectPediatrics
dc.titleDoes growth hormone treatment advance bone age?
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication0ea2245f-bcba-4a84-b68a-fdbc43ac8913
relation.isAuthorOfPublication73e10417-4d1e-4216-b057-4c0a0cf76dc1
relation.isAuthorOfPublication2d1c6521-88a9-4270-9918-92f16f98006c
relation.isAuthorOfPublication.latestForDiscovery0ea2245f-bcba-4a84-b68a-fdbc43ac8913

Files

Collections